The Challenge
When Illinois Governor signed SB 2886 in late 2024, compliance teams at healthcare organizations, insurers, and employers faced an immediate question: what exactly counts as biomarker data, and how does it differ from the genetic information they're already protecting?
This challenge is real. GIPA carries a private right of action with damages of $2,500 per negligent violation and $15,000 per intentional or reckless violation. The law has generated a steady stream of private lawsuits, many in the employment context. With amendments taking effect January 1, 2027, organizations need to understand whether their existing genetic information controls cover the expanded definition or if they need to redesign entire data handling workflows.
The core problem: biomarker data isn't just genetic sequences anymore. Under SB 2886, a "biomarker" includes "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention." This includes gene mutations, protein expression, and potentially any measurable biological indicator extracted from tissue, blood, or fluid samples. "Biomarker testing" now covers single-analyte tests, multiplex panel tests, and partial or whole genome sequencing.
For compliance officers, this raises immediate classification questions. Does a routine blood panel that measures protein markers fall under GIPA? What about cancer screening tests that look for tumor markers? If you're running employee wellness programs with biometric screening, which data points now require written consent under GIPA's confidentiality protections?
The Environment and Constraints
Organizations handling biomarker data in Illinois operate under three overlapping compliance pressures.
First, GIPA's existing genetic information protections already required written consent, confidentiality safeguards, and strict limits on insurer and employer use. The law isn't new, but its scope is about to expand dramatically.
Second, many organizations already handle biomarker data under Health Insurance Portability and Accountability Act requirements. HIPAA Security Rule and HIPAA Privacy Rule establish baseline protections for protected health information, but GIPA goes further. HIPAA allows certain disclosures for treatment, payment, and healthcare operations without individual authorization. GIPA does not. Under SB 2886, biomarker information remains confidential and privileged, releasable only to the tested individual and persons specifically authorized in writing.
Third, the January 1, 2027 effective date creates a fixed timeline. Organizations can't wait for regulatory guidance or case law to clarify ambiguities. They need to audit existing data flows, identify biomarker information, and implement controls before the law takes effect.
The constraint most teams struggle with: distinguishing biomarker testing from routine clinical diagnostics. The bill defines biomarker testing as "the analysis of a patient's tissue, blood, or fluid biospecimen for the presence of a biomarker." That's broad. It includes tests your organization might not have classified as genetic information under the previous GIPA framework.
The Approach Organizations Are Taking
Compliance teams addressing SB 2886 are starting with data inventory and classification. You can't protect biomarker information if you don't know where it lives in your systems.
The first step: map every process that collects, stores, or uses tissue, blood, or fluid analysis results. This includes laboratory information systems, electronic health records, wellness program databases, and any third-party platforms processing test results. For each data flow, ask whether the test measures a biological characteristic that could indicate normal processes, pathogenic processes, or therapeutic responses.
Once you've identified biomarker data, apply GIPA's expanded requirements:
Confidentiality controls: Biomarker testing information must be treated as confidential and privileged. This means access controls stricter than standard protected health information. Implement Role-Based Access Control that limits biomarker data visibility to individuals with explicit authorization. Log every access. If your current system allows broad "treatment, payment, operations" access to genetic information, you'll need to narrow permissions for biomarker data.
Consent documentation: GIPA requires written consent for the release of biomarker testing information. Review your current consent forms. Do they specifically mention biomarker testing, or do they only reference genetic testing? Update templates to explicitly cover biomarker analysis. Ensure consent forms identify who will receive the information and for what purpose. Generic "for healthcare purposes" language won't satisfy GIPA's specificity requirement.
Insurer restrictions: If you're an insurer, SB 2886 prohibits seeking biomarker information for underwriting purposes, nontherapeutic purposes, or in connection with accident or health insurance policies unless the individual voluntarily submits favorable results. Audit your underwriting questionnaires, application forms, and medical information requests. Remove any language that could be interpreted as soliciting biomarker data. Train underwriters on the distinction between permissible health information requests and prohibited biomarker inquiries.
Employer limitations: Employers can't solicit, request, or require biomarker information as a condition of employment. If you run employee wellness programs that include biometric screening, review what you're collecting. Are you measuring protein markers, cholesterol levels, or other biomarkers? If so, participation must be genuinely voluntary, and you must obtain written consent that complies with GIPA's release restrictions.
Disclosure protocols: No person may disclose biomarker test results in a manner that permits identification of the subject unless an exception applies. This affects how you share information with researchers, public health authorities, or other third parties. Implement de-identification procedures that meet GIPA's standard, not just HIPAA's Safe Harbor or Expert Determination methods. Document every disclosure, the legal basis, and whether it required individual authorization.
Results and What's at Stake
Organizations that implement these controls before January 1, 2027 avoid the immediate litigation risk that comes with GIPA's private right of action. Those that don't face exposure on every biomarker data point they collect, store, or share without proper authorization.
The financial risk is measurable: $2,500 per negligent violation, $15,000 per intentional or reckless violation. If you're processing biomarker data for thousands of individuals without compliant consent forms, the exposure scales quickly.
Beyond litigation risk, organizations that get this right position themselves for the broader regulatory trend. Illinois isn't alone in expanding health privacy protections beyond traditional genetic information. As biomarker testing becomes central to personalized medicine, other states will likely follow with similar expansions. Building GIPA-compliant controls now creates a foundation that adapts to future regulatory requirements.
What Teams Wish They'd Known Earlier
The biggest lesson from early GIPA compliance work: don't wait for perfect clarity on what counts as biomarker data. The definition is broad by design. If you're analyzing biological characteristics from tissue, blood, or fluid samples, treat it as covered until you have a documented legal opinion stating otherwise.
Second lesson: consent form updates take longer than you expect. You're not just revising language, you're changing how you obtain, document, and store authorization. If you use electronic consent systems, those need configuration changes. If you rely on paper forms, you need printing, distribution, and training timelines. Start this work in 2025, not 2026.
Third lesson: insurer and employer restrictions require operational changes, not just policy updates. Underwriters need training on what they can't ask. HR teams need new protocols for wellness program data. These aren't compliance checkbox exercises, they're workflow redesigns.
Takeaways for Your Team
If you handle biomarker data in Illinois, you have until January 1, 2027 to implement SB 2886 controls. Start with these actions:
Conduct a biomarker data inventory: Identify every system, process, and third party that collects or uses tissue, blood, or fluid analysis results. Don't limit your review to systems you currently classify as "genetic information" repositories.
Update consent forms and authorization procedures: Ensure written consent explicitly covers biomarker testing and identifies authorized recipients. Review forms with legal counsel to confirm GIPA compliance.
Restrict insurer and employer access: If you're an insurer, remove biomarker information requests from underwriting processes. If you're an employer, ensure wellness program participation is voluntary and supported by compliant written consent.
Implement access controls and audit logging: Biomarker information requires confidentiality protections beyond standard health information. Limit access to individuals with written authorization and log every disclosure.
Train staff on the expanded definition: Make sure laboratory staff, clinicians, underwriters, and HR professionals understand what biomarker data includes and what restrictions apply.
The expansion of GIPA reflects a regulatory recognition that biomarker data carries the same privacy risks as genetic sequences. Your compliance program needs to reflect that reality before the law takes effect.
